A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.

doi:10.1016/j.drup.2023.100957

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 May 2023

Liang Qian, Gong Miaomiao, Zou Jing-Hua, Luo Ming-Yu, Jiang Lu-Lu, Wang Cheng, Shen Ning-Xiang, Zhang Mo-Cong, Xu Lu, Lei Hui-Min, Zhang Ke-Ren, Zhang Rui, Zhuang Guanglei, Zhu Liang, Chen Hong-Zhuan, Zhou Lu, Shen Ying

Abstract excerpt

Resistance to epidermal growth factor receptor (EGFR) inhibitors, from the first-generation erlotinib to the third generation osimertinib, is a clinical challenge in the treatment of patients with EGFR-mutant lung adenocarcinoma. Our previous work found that a novel allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1), HKB99, restrains erlotinib resistance in lung adenocarcinoma cells. However, the role of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Interleukin-6

Share to Janus Kinase 2

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 36990047
DOI: 10.1016/j.drup.2023.100957

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.PMID 36990047Read ↗

Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.Semantic proximity Read ↗

Co-targeting MERTK and EGFR with a Bispecific Antibody Overcomes Drug Resistance Across Mutations in Exons 19, 20, and 21Semantic proximity Read ↗

Ganoderma microsporum immunomodulatory protein combined with KRASG12C inhibitor impedes intracellular AKT/ERK network to suppress lung cancer cells with KRAS mutation.Semantic proximity Read ↗

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.Semantic proximity Read ↗

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.Semantic proximity Read ↗

FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway.Semantic proximity Read ↗

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.Semantic proximity Read ↗

Integrin αV Inhibition by GMI, a Ganoderma Microsporum Immunomodulatory Protein, Abolish Stemness and Migration in EGFR-Mutated Lung Cancer Cells Resistant to Osimertinib.Semantic proximity Read ↗

Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1.Semantic proximity Read ↗

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.Semantic proximity Read ↗

Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth.Semantic proximity Read ↗

The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.